No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LH240719P195000
- 0.20
- -0.44-68.75%
15min DelayClose Jul 12 15:59 ET
0.23High0.15Low
0.23Open0.64Pre Close14 Volume814 Open Interest195.00Strike Price269.00Turnover48.93%IV5.51%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type-0.1698Delta0.0201Gamma175.46Leverage Ratio-0.2767Theta-0.0053Rho-29.79Eff Leverage0.0651Vega
Intraday
- 5D
- Daily
News
Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
Oppenheimer's Top SMID Ideas Within High-growth Themes
Drug Middlemen Pay Higher Prices to Their Own Pharmacies, Says FTC
(July 9): Drug middlemen paid their own mail-order pharmacies as much as 200 times more than the price at rival pharmacies for commonly prescribed cancer drugs, allowing them to bring in at least US$1 billion (RM4.71 billion) in excess revenue and potentially raising the costs to patients, the US Federal Trade Commission (FTC) found in an interim study.
Here's What to Expect From Labcorp Holdings' Next Earnings Report
Laboratory Corp. Price Target Raised to $215.00/Share From $210.00 by Evercore ISI Group
Laboratory Corp. Price Target Raised to $215.00/Share From $210.00 by Evercore ISI
Laboratory Corp. Is Maintained at In-Line by Evercore ISI Group
Laboratory Corp. Is Maintained at In-Line by Evercore ISI
Comments
The company's stock seems overpriced compared to its peers, suggesting limited potential for further growth. Its low beta indicates it may not align with industry levels soon.
Insider selling shares below current price suggests contentment with lower valuation. Lack of insider buying and low insider ownership make the company a cautious investment choice.
Investors' optimism about Laboratory Corporation's performance could lead to inflated stock prices. The high share price puts existing and new shareholders at potential risk, possibly paying an unnecessary premium.
Labcorp's acquisition set to fortify its Massachusetts presence and push its goal of broadening cost-effective lab testing. The partnership with Baystate Health aims at promoting efficient, advanced healthcare services and improving patient and provider experience.
Read more